All articles by cms admin

cms admin

KAI partners Ono to develop KAI-4169

KAI Pharmaceuticals has entered into an agreement with Ono Pharmaceutical for the development and commercialisation of KAI-4169 in Japan. KAI-4169, an intravenous formulation for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease-mineral and bone diso

Teva signs antiviral drug development agreement with Cocrystal Discovery

Teva Pharmaceutical Industries has signed a license and share purchase agreement with Cocrystal Discovery, a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases. Cocrystal Discovery w

European over-prescribing becoming “chronic”

The over-prescription of medicines in Europe, particularly for the elderly, is becoming chronic, according to a study conducted by Salzburg Medical University, Austria. The study found that 36% of prescriptions given to patients with an average age of 82 were unnecessary, while 30% o

NICE recommends AstraZeneca’s Brilique

A UK health watchdog has recommended AstraZeneca drug Brilique (ticagrelor) for the treatment of acute coronary syndromes caused by blood clots. In a final draft guidance, the National Institute for Health and Clinical Excellence (NICE) backed the use of the drug in combination with asp

Features

Trial and error: site selection for clinical studies

An often underrated process, site selection is one of the most significant factors for a successful clinical trial. Ahead of Arena International’s Achieve Operational Efficiency in Clinical Trials conference, Elisabeth Fischer speaks to Marta Rayo Lunar, project manager at drug development company Advancell, about the right strategies for selecting sites capable of meeting equipment, staff and trial patient requirements.

FDA launches investigation into GlaxoSmithKline’s Zofran

The US Food and Drug Administration (FDA) has launched an investigation into GlaxoSmithKline’s Zofran medication, used to treat nausea, following concerns that the drug could distort the electrical activity of the heart. The investigation, which will also include generic versions of t

AB Science receives FDA approval to commence asthma drug study

AB Science has obtained investigational new drug status from the US Food and Drug Administration (FDA), allowing it to commence its Phase III study of masitinib in severe persistent asthma. Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells, which play

ConjuChem commences diabetes drug trial

ConjuChem has initiated patient enrolment in a Phase II clinical trial of its proprietary GLP-1 receptor agonist drug CJC-1134-PC in patients with type 2 diabetes who are receiving metformin monotherapy. The randomised, double-blind and placebo-controlled dose-ranging study will involve

Technology Strategy Board to support healthcare research projects

The Technology Strategy Board, in collaboration with the Engineering and Physical Sciences Research Council, is set to invest up to £9m to support collaborative research projects focused on nanoscale technology-enabled solutions for the healthcare sector. The competition supports applic

Acceleron begins anaemia drug study

Acceleron Pharma has initiated a Phase I clinical study of ACE-536, a ligand trap that increases red blood cells and haemoglobin by inhibiting members of the TGF-beta super family for the treatment of anaemia. The multiple-dose, dose-escalating Phase I study is designed to assess the sa